Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Particle Sciences sells T-COTE(R) Line of Microfine Titanium Dioxides to Sensient

Abstract:
Particle Sciences announced today that it has sold T-COTE, its proprietary line of microfine titanium dioxide, to Sensient. With the sale, Sensient assumes all marketing and sales responsibilities and acquires the associated trademarks and existing business. Particle Sciences will remain involved during the transition for technical support. The sale does not result in any change to the product, its specifications or method and location of manufacture.

Particle Sciences sells T-COTE(R) Line of Microfine Titanium Dioxides to Sensient

BETHLEHEM, PA | Posted on October 7th, 2008

Particle Science's has been a pioneer in nanotechnology. Its staff invented, among other things, Z-COTE, microfine zinc oxide, a product that was sold to BASF in 1999. These pigments are primarily used as sunscreens. Particle Sciences also developed several surface treatments for these and other particles. 'Particle Sciences has been at the cutting edge of fine particle technology for some time. We have a history of developing commercially successful products for ourselves and others,' said Garry Gwozdz, Director of Formulation Services at the company.

The sale is in keeping with Particle Sciences growth plan as it focuses on its pharmaceutical development services. According to Dr. Robert Lee, VP Pharmaceutical Development, 'Particle Sciences started, in 1991, as a topical formulation lab specializing in particulate API's. It has evolved into a leading provider of pharmaceutical development services ranging from preformulation to encapsulation to clinical trial material manufacturing. We remain expert in nano-delivery systems and provide a full suite of formulation and analytical services to our clients.'

####

About Particle Sciences
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.

For more information, please click here

Contacts:
Maureen Cochran

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Acquisitions/Mergers/Splits

The concept of creating «brain-on-chip» revealed: A team of scientists is working to create brain-like memristive systems providing the highest degree of adaptability for implementing compact and efficient neural interfaces, new-generation robotics, artificial intelligence, perso May 29th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020

Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project